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ABSTRACT
Focal adhesion kinase (FAK) has important functions in bone homeostasis but its role in early osteoprogenitor cells is unknown. We
show herein that mice lacking FAK in Dermo1-expressing cells exhibited low bone mass and decreased osteoblast number. Mecha-
nistically, FAK-deficient early osteoprogenitor cells had decreased proliferation and significantly reduced mammalian/mechanistic
target of rapamycin complex 1 (mTORC1) signaling, a central regulator of cell growth and proliferation. Furthermore, our data showed
that the pharmacological inhibition of FAK kinase-dependent function alone was sufficient to decrease the proliferation and compro-
mise the mineralization of early osteoprogenitor cells. In contrast to the Fak deletion in early osteoprogenitor cells, FAK loss in Col3.6
Cre-targeted osteoblasts did not cause bone loss, and Fak deletion in osteoblasts did not affect proliferation, differentiation, and
mTORC1 signaling but increased the level of active proline-rich tyrosine kinase 2 (PYK2), which belongs to the same non–receptor
tyrosine kinase family as FAK. Importantly, mTORC1 signaling in bone marrow stromal cells (BMSCs) was reduced if FAK kinase was
inhibited at the early osteogenic differentiation stage. In contrast, mTORC1 signaling in BMSCs was not affected if FAK kinase was
inhibited at a later osteogenic differentiation stage, in which, however, the concomitant inhibition of both FAK kinase and PYK2
kinase reduced mTORC1 signaling. In summary, our data suggest that FAK promotes early osteoprogenitor cell proliferation by
enhancing mTORC1 signaling via its kinase-dependent function and the loss of FAK in osteoblasts can be compensated by the upre-
gulated active PYK2. © 2020 American Society for Bone and Mineral Research.
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Introduction
Focal adhesion kinase (FAK) is an intracellular non–receptortyrosine kinase. Since its discovery,(1) numerous studies have
shown critical roles of FAK in cell adhesion, migration, prolifera-
tion, and differentiation.(2,3) FAK can function through its
kinase-dependent and kinase-independent functions in differ-
ent cellular processes.(4–6)
Osteoblasts from osteoporotic human bone had decreased
FAK activation compared to osteoblasts from non-osteoporotic
control,(7) suggesting an important role of FAK in human bone
health. However, our understanding of the roles and mecha-
nisms of FAK in regulating bone homeostasis is very limited. To
circumvent the embryonic lethality of Fak global knockout,(8)
Fak has been deleted by different osteoblast-targeted Cre trans-
genic mice.(9–11) An earlier study showed that Fak deletion in
osteoblasts by Col2.3-Cre does not affect mouse bone develop-
ment.(9) Our recent study showed that Fak deletion in Osterix-
expressing committed osteoblast precursor cells leads to osteo-
penia in mice.(10)
Mammalian/mechanistic target of rapamycin complex
1 (mTORC1) is a major regulator of protein synthesis,(12) and it
controls cell growth and proliferation through two downstream
effectors including the ribosomal protein S6 kinases (S6K1 and
S6K2) and the eukaryotic translation initiation factor 4E (eIF4E)-
binding proteins (4EBP1, 4EBP2, and 4EBP3).(13) S6K1 is required
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for 50-terminal oligopyrimidine (50-TOP) mRNA translation.
Because ribosomal proteins and translation elongation factors
are encoded by 50-TOP mRNAs, signaling through the phosphor-
ylation of S6K1 via mTORC1 activation promotes ribosomal bio-
genesis and enhances protein biosynthesis. The ribosomal
protein S6 is the best known S6K1 substrate and its phosphoryla-
tion status faithfully reflects the S6K1 activity. 4EBP1 is a repres-
sor of translation initiation; upon phosphorylation by mTORC1
activation, 4EBP1 releases from eIF4E, allowing eIF4E to bind with
eIF4G to initiate cap-dependent translation.(13)
The Dermo1 (Twist2)-Cre mouse is one of the commonly used
transgenic mice to target early osteoprogenitor cells.(14,15) Inacti-
vation of β1-integrin by Dermo1-Cre leads to severely impaired
skeletal development.(16) Importantly, integrin-mediated cell
adhesion to extracellular matrix activates FAK, which is the key
component of the signal transduction pathways triggered by
integrins.(17–19) To directly determine the role of FAK in early
osteoprogenitor cells in bone homeostasis, we generated Fak
conditional knockout mouse in which Fak was deleted by Der-
mo1-Cre. In addition, we used Col3.6-Cre(20) to delete Fak in oste-
oblasts. We showed that Fak deletion by Dermo1-Cre but not by
Col3.6-Cre led to bone mass decrease that was accounted for by
the decreased cell proliferation and decreased mTORC1 signal-




The floxed Fak (Fakflox/flox), Dermo1-Cre, and Col3.6-Cre, and
ROSA26-RFP (Ai14)mice have been described.(5,20–22) Fakflox/flox,Der-
mo1-Cre, and Col3.6-Cre mice were backcrossed for at least eight
generations onto a C57BL/6 background. Male Fakflox/flox mice were
bred with female Fakflox/+;Dermo1-Cre mice to generate Fakflox/flox
(Control), Fakflox/+;Dermo1-Cre (CHet) and Fakflox/flox;Dermo1-Cre
(CKODermo1) mice. Male Fakflox/flox;RFP/RFP mice were crossed with
female Fakflox/+;Dermo1-Cre mice to generate Fakflox/+;Dermo1-Cre;
Ai14 (hereafter, CHet-RFP) and Fakflox/flox;Dermo1-Cre; Ai14 (hereaf-
ter, CKODermo1-RFP) mice. Male Fakflox/flox;Col3.6-Cremice were bred
with female Fakflox/flox mice to generate Fakflox/flox (Control) and
Fakflox/flox;Col3.6-Cre (CKO3.6) mice. Mice were housed under
pathogen-free conditions at 22C  2C on a 12:12-hour light/
dark cycle. Mice were euthanized using overdosing carbon diox-
ide. All the experimental procedures were carried out with the
approval of the Institutional Animal Care and Use Committee at
the University of Michigan.
Micro–computed tomography analysis
Femurs and third lumbar vertebra were dissected and analyzed
by micro–computed tomography (μCT) using an eXplore Locus
SP (GE Healthcare Pre-Clinical Imaging, London, ON, Canada) as
we described.(23) The μCT image used for the analysis of vertebra
cortical bone area was established 0.63 mm inferior to the end of
cranial growth plate (Fig. S1). The analyzer was blind to the iden-
tification of the samples.
Histomorphometry
Static histomorphometry was performed similarly to what we
described.(23–25) All parameters were measured according to
the Report of the American Society of Bone andMineral Research
Histomorphometry Nomenclature Committee.(26) The analyzer
was blind to the identification of the samples.
Bone marrow stromal cells isolation and culture
Bone marrow stromal cells (BMSCs) were collected from 6-week-
oldmice in the sameway as described.(10) Briefly, the end of each
femur and tibia was cut and cells were flushed using α-MEM.
Then the cells were cultured in a 100-mm dish for 3 days before
half change of the basic medium including α-MEMmedium, 10%
fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL of
streptomycin, followed by a full medium change on day 7 and
every other day afterward. In some experiments, the adherent
cells were trypsinized and plated for experiments on day 10.
BMSCs, osteogenic differentiation, and histochemical
assay
BMSCs isolated from control, CHet and CKODermo1 mice were
seeded in a 6-well plate at 1.3 × 107 cells/well and cultured as
described in the section of “Bone marrow stromal cells isolation
and culture”. The osteogenic medium containing 50 mg/mL of
ascorbic acid and 10mM of beta glycerophosphate was used
on day 7 and changed every other day afterward. The alkaline
phosphatase (ALP) staining and Alizarin red (AR) staining were
performed on day 10 and day 21, respectively, as described.(10)
Crystal violet staining was performed on day 10. Briefly, cells
were fixed with 100% methanol at −20C for 15 mins and
stained with 0.5% crystal violet solution at room temperature
for 15 mins. ImageJ software (NIH, Bethesda, MD, USA; https://
imagej.nih.gov/ij/) was used to measure the size of the colony
after ALP staining and crystal violet staining. BMSCs collected
from control and CKOCol3.6 mice were seeded in 12-well plate
at 70,000 cells/well after being trypsinized on day 10. After
24 hours, cells were subjected to osteogenic medium that was
changed every other day. ALP staining and AR staining were per-
formed on day 7 and day 21, respectively.
FAK kinase inhibitor and FAK/PYK2 dual inhibitor
treatment
BMSCs isolated from wild-type mice and CKOCol3.6 mice were
seeded in a 6-well plate at 1.3 × 107 cells/well. FAK kinase inhib-
itor PF-573,228 (Apexbio Technology LLC, Houston, TX, USA;
#B1523) or FAK/PYK2 dual inhibitor PF-562,271 (Apexbio Tech-
nology; #A8320) was added with different doses at different time
points every other day. Cell lysates were collected at indicated
time points for western blot analysis. ALP staining and crystal
violet staining were performed on day 10. Von Kossa staining
was performed on day 21. In brief, cells were fixed using 70% eth-
anol in room temperature for 30 mins, hydrated with distilled
water (dH2O) and then incubated in 5% silver nitrate at 37C
for 1 hour before being exposed to light for 30 mins.
Proliferation assay
For experiments using control and CKOCol3.6 mice, BMSCs were
seeded in a 12-well plate at 70,000 cells/well after trypsinizing
the mesenchymal colonies on day 10. For the experiments using
other mice, BMSCs were directly seeded in 12-well plate at
5 × 106 cells/well. Cells were trypsinized and the cell number
was counted on day 3 and day 7. Ki67 immunostaining was per-
formed on day 3 and day 7 as described.(10) Briefly, cells were
fixed with 4% paraformaldehyde and immunostained using
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anti-Ki67 antibody (Cell Signaling Technology, Beverly, MA,
USA; #9129).
Western blot
Western blot was performed as described.(10) Antibody informa-
tion is described as follows: anti-β-catenin: BD Transduction
Laboratories, Lexington, KY, USA; #610153; anti-Vinculin: Sigma-
Aldrich, St. Louis, MO, USA; #V4505; anti-p-PYK2 (Tyr402): Cell
Signaling Technology; #3291; anti-PYK2: Cell Signaling Technol-
ogy; #3292; anti-p-FAK (Tyr397): Cell Signaling Technology;
#3283; anti-FAK: Santa Cruz Biotechnology, Santa Cruz, CA,
USA; #SC-558; anti-p-S6 (Ser240/244): Cell Signaling Technology;
#5364; anti-S6: Cell Signaling Technology; #2217; anti-p-mTOR
(Ser2448): Cell Signaling Technology; #2971; anti-mTOR: Cell Sig-
naling Technology; #2972; anti-p-4E-BP1 (Thr37/46): Cell Signal-
ing Technology; #2855; anti-4E-BP1: Cell Signaling Technology;
#9452; anti-p-AKT (Ser473): Cell Signaling Technology; #4060;
and anti-AKT: Cell Signaling Technology; #4691.
Statistics
For the comparison between two groups, Student’s t test was
used. For the comparison in more than two groups, one-way
ANOVA with Tukey’s multiple comparison tests were performed
using GraphPad Prism 8.0 (GraphPad Software, Inc., La Jolla, CA,
USA). For the comparison of two groups that have two different
variables, two-way ANOVA with Sidak’s multiple comparison
tests were performed using GraphPad Prism 8.0.
Results
Deletion of Fak in Dermo1-expressing cells leads to
osteopenia in mice
To determine the role of FAK in early osteoprogenitor cells, we
deleted Fak using Dermo1-Cre. Dermo1-Cremice were generated
by inserting the Cre recombinase gene within the first exon of
Dermo1, thus resulting in haploinsufficiency.(21) To determine
whether Dermo1 haploinsufficiency affects normal bone devel-
opment, we analyzed Dermo1-Cre/+ and littermate wild-type
mice. Our data showed that Dermo1 haploinsufficiency did not
affect body weight (Fig. S2) and bone mass (Fig. S3) in both male
and femalemice. Fak deletion in Dermo1-expressing cells did not
affect the body weight and femoral bone length of male mice
and it slightly decreased the body weight without affecting the
femoral bone length of female mice at 2 months of age
(Fig. S4). To determine the FAK deletion efficiency, western blot
was performed using lysates extracted from femurs of
2-month-old mice. Our data showed that FAK was similarly
deleted in male and female mice (Fig. S5). μCT analysis showed
that Fak deletion in Dermo1-expressing cells led to a significant
decrease in femoral trabecular bone mass (Fig. 1A–E) and a sig-
nificant decrease in femoral cortical bone size (Fig. 1F–H) in
2-month-old male mice. Because of the concomitant decrease
in both total cross-sectional area and marrow area, there was
no change in cortical area and thickness in CKODermo1 male mice
(Fig. 1I,J). In vertebra, Fak deletion led to a significant decrease in
both trabecular and cortical bone mass in male mice (Fig. S6).
However, Fak deletion in Dermo1-expressing cells did not affect
femoral bonemass in 2-month-old female mice although female
CKODermo1 mice showed the similar trend in the decrease of tra-
becular thickness and total cross-sectional area, and a decrease
in marrow area (Fig. S7). Our data suggested that this gender
difference was not due to the difference in FAK deletion effi-
ciency between male and female CKODermo1 mice (Fig. S5). The
reason underlying this gender difference is unclear.
Histomorphometry analysis also showed the decrease of fem-
oral trabecular bone mass in CKODermo1 male mice (Fig. 2A–E),
which was accounted for by a significant decrease in osteoblast
number and surface without change in osteoclast number and
surface (Fig. 2F–I). In addition, Fak deletion in Dermo1-expressing
cells did not affect the bonemarrow adipocyte number (data not
shown).
Fak deletion in Dermo1-expressing cells leads to
decreased BMSC proliferation
To elucidate the mechanism responsible for the decreased bone
mass and decreased osteoblast number in CKODermo1 mice, we
determined the effect of Fak deletion on the proliferation of early
mesenchymal lineage cells using a primary BMSC culture system.
Because of the heterogeneity nature of BMSC culture, first we
performed lineage mapping experiments by introducing
ROSA26-RFP reporter into CHet and CKODermo1 mice. BMSCs
were isolated from CHet-RFP and CKODermo1-RFP mice and the
percentage of RFP-positive cells within BMSC colonies was ana-
lyzed. Our data showed that there was a significant decrease in
the percentage of RFP-positive cells in CKODermo1-RFP group
compared to CHet-RFP group (Fig. 3A,B), suggesting that the
Fak-deleted BMSCs had compromised ability to increase their
number.
To determine the mechanism that was accountable for the
decrease in the percentage of RFP-positive cells in the CKO-
Dermo1-RFP group, we performed immunofluorescence staining
of Ki67, a proliferation marker. Our data showed that there were
significantly less Ki67-positive cells within the RFP-positive cells
of CKODermo1-RFP group compared to that of CHet-RFP group
in day 7 culture, while there was no difference between these
two groups at day 3 (Fig. 3C,D). Consistent with a decrease in pro-
liferation, BMSCs isolated from CKODermo1 mice had a significant
decrease in cell number in day 7 culture (Fig. 3E). To determine
whether Dermo1 haploinsufficiency itself affects the BMSC prolif-
eration, we performed similar experiments using BMSCs isolated
from Dermo1-Cre/+ mice and their wild-type littermates. Our
data showed that the two groups had a comparable percentage
of Ki67-positive BMSCs and total cell number (Fig. S8).
Next, we determined the effect of Fak deletion in Dermo1-
expressing cells on formation of fibroblastic colony-forming
units (CFU-F). Our data showed that the CKODermo1 group had a
significant decrease in both CFU-F number and size (Fig. 3F–H).
Similarly, the CKODermo1 group had a significant decrease in both
the number and size of ALP-positive CFU-F (CFU-ALP) (Fig. S9A–
C). In addition, the CKODermo1 group had significantly compro-
mised mineralization (Fig. S9D,E).
FAK kinase inhibition leads to decreased BMSC
proliferation
FAK has both kinase-dependent and kinase-independent func-
tions.(4,27) To determine the contribution of the kinase-
dependent function of FAK to BMSC proliferation, we utilized
the specific FAK kinase inhibitor PF-573,228,(28) a potent, ATP-
competitive, reversible inhibitor of FAK kinase activity that was
developed to treat various cancers.(29,30) It was shown that PF-
573,228 can block >75% to 80% endogenous FAK activity at
the concentration of 0.3μM to 3μM in different cell types.(28)
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Thus, we first determined the effect of PF-573,228 on the inhibi-
tion of FAK kinase activation at the dose of 0.1μM to 2μM. Our
data showed that 1μM PF-573,228 effectively inhibited FAK
kinase activation shown by the significantly decreased
phospho-FAKTyr397 level (Fig. 4A,B). When BMSCs isolated from
CHet-RFP mice were treated with 1μM PF-573,228, there was a
significant decrease in the percentage of Ki67-positive cells
within the RFP-positive cells (Fig. 4C,D) and a significant decrease
in total cell number (Fig. 4E). Furthermore, PF-573,228 signifi-
cantly decreased CFU-F number and size (Fig. 4F–H), ALP-
positive CFU-F number and size (Fig. S10A–C) andmineralization
(Fig. S10D,E) of BMSCs. Thus, our data suggested that the loss of
FAK’s kinase-dependent function contributed significantly to the
proliferation inhibition in Fak-deleted Dermo1-expressing
BMSCs.
FAK deficiency in Dermo1-expressing cells leads to
decreased mTORC1 signaling
To elucidate the molecular mechanism that was responsible for
the decreased proliferation in CKODermo1 BMSCs, we started with
determining the effect of Fak deletion in Dermo1-expressing
Fig. 1. Fak deletion in Dermo1-expressing cells leads to osteopenia in mice. μCT analysis were performed in femurs of 2-month-old male Fakflox/flox
(Control), Fakflox/+;Dermo1-Cre (CHet), and Fakflox/flox;Dermo1-Cre (CKODermo1) mice. (A–E) Femoral trabecular bone: (A) representative μCT image (scale
bar = 500 μm), (B) BV/TV, (C) Tb.N, (D) Tb.Th, and (E) Tb.Sp. (F–J) Femoral cortical bone: (F) representative μCT image (scale bar = 300 μm), (G) Tt.Ar, (H)
Ma.Ar, (I) Ct.Ar, and (J) Ct.Th. Values are presented as median and interquartile range (n = 8 for control group, n = 9 for CHet group, and n = 9 for CKODermo1
group). BV/TV = bone volume fraction; Ct.Ar = cortical bone area; Ct.Th = average cortical thickness; Ma.Ar =marrow area; Tb.N = trabecular number; Tb.Sp
= trabecular spacing; Tb.Th = trabecular thickness; Tt.Ar = total cross-sectional area inside the periosteal envelope.
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cells on β-catenin level because we had shown that Fak deletion
in Osterix-expressing cells leads to a significant decrease in
β-catenin level.(10) First, we determined the FAK deletion effi-
ciency in our BMSC cultures. In most of the experiments (five of
nine) performed, there was sufficient FAK deletion; however, in
some experiments (four of nine), FAKwas not sufficiently deleted
(Fig. S11A). For the cell signaling study, we focused on the five
experiments with sufficient FAK deletion. Our data showed that
Fak deletion in Dermo1-expressing cells did not affect β-catenin
level (Fig. 5A,B). This is unexpected because our previous study
showed Fak deletion in Osterix-expressing cells significantly
decreases β-catenin level.(10) Next, we examined the effect of
Fak deletion in Dermo1-expressing cells on the mTORC1
signaling because our previous study suggested that mTORC1
signaling is an important positive regulator on proliferation of
osteoprogenitor cells.(31) Our data showed that Fak deletion in
Dermo1-expressing cells significantly inhibited mTORC1 activity
showed by the decrease in the level of phospho-mTOR and
phospho-S6 (Fig. 5A,B). However, there was no change in
phospho-4EBP1, the other downstream effector of mTORC1
(Fig. 5A,B). In addition, Fak deletion in Dermo1-expressing cells
significantly decreased phospho-AKT level and there was no
change in phospho-PYK2 level (Fig. 5A,B). Of note, in the experi-
ments in which FAK was not sufficiently deleted, the levels of
phospho-S6 and phospho-AKT were not decreased (Fig. S11B),
further supporting the connection between FAK and
Fig. 2. Fak deletion in Dermo1-expressing cells leads to decreased osteoblast number. Histomorphometric analysis was performed in femurs of 2-month-
old male Fakflox/flox (Control), Fakflox/+;Dermo1-Cre (CHet), and Fakflox/flox;Dermo1-Cre (CKODermo1) mice. (A) Representative histological image (scale
bar = 0.7 mm), (B) BA/TA, (C) Tb.N, and (D) Tb.Th, (E) Tb.Sp, (F) N.Ob/BS, (G) Ob.S/BS, (H) N.Oc/BS, and (I) Oc.S/BS. Values are presented as median and inter-
quartile range (n = 7 for control group, n = 9 for CHet group, and n = 7 for CKODermo1 group). BA/TA = bone area per tissue area; N.Ob/BS = osteoblast
number per bone surface; Ob.S/BS = osteoblast surface per bone surface; N.Oc/BS = osteoclast number per bone surface; Oc.S/BS = osteoclast surface
per bone surface; Tb.N = trabecular number; Tb.Sp = trabecular spacing; Tb.Th = trabecular thickness.
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AKT/mTORC1 signaling. To further determine the regulation of
mTORC1 activity by FAK in Dermo1-expressing BMSCs, we per-
formed immunofluorescence staining using antibody against
phospho-S6. Our data showed a similar expression pattern
between CHet-RFP and CKODermo1-RFP in day 3 culture; however,
there was a significant decrease in the percentage of phospho-
S6 positive cells within RFP-positive cells in the CKODermo1-RFP
group in day 7 culture (Fig5C,D).
Fak deletion in osteoblasts does not affect bone
development
Our current study and previous study(10) showed that FAK in
Dermo1-expressing early osteoprogenitor cells and Osterix-
expressing committed osteoblast precursors plays important
role in bone development. To determine the effect of Fak dele-
tion in osteoblasts on bone development, we analyzed Fak
Fig. 3. Fak deletion in Dermo1-expressing cells leads to decreased BMSC proliferation. (A,B) Analysis of percentage of RFP-positive cells in clonal BMSCs isolated
from CHet-RFP and CKODermo1-RFPmice: (A) representative fluorescent images. Red indicates RFP-positive signal and blue (DAPI staining) indicates nucleus (scale
bar = 100 μm); (B) quantification of the percentage of RFP-positive cells in day 7 culture illustrated inA. Datawere the average of 6 independent experiments. (C,D)
Analysis of Ki67-positive cells in the population of RFP-positive clonal BMSCs isolated from CHet-RFP and CKODermo1-RFP mice: (C) representative fluorescent
images in day 3 (D3) and day 7 (D7) cultures (scale bar = 20 μm); yellow arrows indicate the RFP+Ki67+DAPI+cells, red arrows indicate the RFP+Ki67−DAPI+cells,
green arrows indicate the RFP−Ki67+DAPI+cells; (D) quantification of the percentage of Ki67 and RFP double-positive cells illustrated in C (n = 3). (E) Quantification
of the cell number cultured for 3 and 7 days in the same culture systemas C (n= 5). (F–H) CFU-F assay of control and CKODermo1 BMSCs: (F) representative image of
crystal violet staining at day 10; (G) quantificationof theCFU-F number; and (H) quantificationof theCFU-F size described in F (n=4). Eachdata point represents the
average of one independent experiment. Values are presented as median and interquartile range. CFU-F = fibroblastic colony-forming unit.
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conditional knockout mice targeted by Col3.6-Cre (CKOCol3.6). In
femoral bone of CKOCol3.6 mice, FAK was efficiently deleted in
association with an increase in phospho-PYK2 level (Fig. 6A).
CKOCol3.6 mice developed normally (Fig. 6B). CKOCol3.6 male mice
had a transient small but statistically significant decrease in body
weight during early postnatal growth with similar body length
(Fig. 6C,D). In addition, Fak deletion in osteoblast did not affect
body weight but slightly decreased body length in CKOCol3.6
female mice (Fig. S12). Furthermore, μCT analysis showed that
CKOCol3.6 male mice had similar trabecular (Fig. 6E–H) and
cortical (Fig. 6I–L) bone parameters compared with control mice.
Histomorphometric analysis showed that there were no changes
in both osteoblast and osteoclast parameters in CKOCol3.6 male
mice compared with the controls (data not shown).
Fak deletion in osteoblasts does not affect BMSC
proliferation and mTORC1 activity
To further determine the extent that FAK regulates osteoblast
function, we performed cellular and signaling studies using
Fig. 4. FAK kinase inhibition leads to decreased BMSC proliferation. (A) Representative western blot image showing that p-FAK level in BMSCs was dose-
dependently suppressed by FAK kinase inhibitor PF-573,228. (B) Quantification of the p-FAK relative level in controls (no treatment and vehicle treatment)
and FAK inhibitor-treated BMSCs. p-FAK was normalized to total FAK protein (n = 3). (C) Representative fluorescent images of BMSCs isolated from CHet-
RFP mice after the treatment with vehicle or FAK inhibitor PF-573,228 for 7 days. Yellow arrows indicate the RFP+Ki67+DAPI+cells; red arrows indicate the
RFP+Ki67−DAPI+cells; green arrows indicate the RFP−Ki67+DAPI+cells. Scale bar = 20 μm. (D) Quantification of the percentage of Ki67 and RFP double pos-
itive cells in the cultures described in C (n = 3). (E) Quantification of the total cell number in the cultures described in C (n = 3). (F) Representative image of
crystal violet staining in BMSC culture treatedwith indicated doses of FAK inhibitor PF-573,228 for 10 days. (G) Quantification of the CFU-F number; and (H)
quantification of the CFU-F size in cultures described in F. Each data point represents the average of one independent experiment (n = 5). Values are pre-
sented as median and interquartile range. CFU-F = fibroblastic colony-forming unit; p-FAK = phospho-FAK.
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BMSCs isolated from CKOCol3.6 and control mice. First, our data
showed that Fak deletion in osteoblasts did not affect the BMSC
proliferation evidenced by the similar percentage of
Ki67-positive cells (Fig. 7A,B) and similar cell number (Fig. 7C) in
the CKOCol3.6 group compared to control group. Second, Fak
deletion in osteoblasts did not compromise the osteogenic dif-
ferentiation and mineralization of BMSCs (Fig. 7D,E). Third,
despite the effective FAK deletion, there was no change in the
levels of phospho-S6 and β-catenin in CKOCol3.6 BMSCs (Fig. 7F,
G). Notably, there was a significant increase in phospho-PYK2
level in the CKOCol3.6 group (Fig. 7F,G).
The inhibition of mTORC1 signaling by FAK kinase
inhibitor is cell differentiation stage-dependent
To elucidate the underlying mechanisms by which FAK was dif-
ferentially required to support the proliferation andmTORC1 sig-
naling in early osteoprogenitor cells versus osteoblasts, we
turned to the strategy of treating BMSCs with FAK kinase inhibi-
tor at different differentiation stages. First, we characterized the
osteogenic differentiation status of BMSCs in our culture model
at different time points. ALP staining showed negative staining
at day 3 but widespread ALP-positive colonies in day 7 and day
10 cultures (Fig. 8A). In addition, we found nearly all cells were
negative for Osterix, a marker of committed osteoblast precur-
sor, at the first 2 days of culture; there were increasingly more
and more Osterix-positive cells starting from day 3 and nearly
all of them were Osterix-positive at day 7 (data not shown). Next,
we designed a treatment regimen using FAK kinase inhibitor to
further determine the effect of FAK kinase inhibition on Wnt/β-
catenin and mTORC1 signaling at different differentiation stages
(Fig. 8B). Our data showed that β-catenin level was only consis-
tently inhibited if FAK kinase inhibitor was added when cells
started to express Osterix, which was around day 3 in our culture
system; on the other hand, AKT and mTORC1 signaling was con-
sistently inhibitedwhen FAK kinase inhibitor was added at earlier
culture in cohort I but not later culture in cohort II (Fig. 8C–E).
Importantly, our data showed that there was a significant
increase in phospho-PYK2 level when FAK kinase inhibitor was
added in later culture but not in early culture (Fig. 8C–E), which
was similar to the increase in phospho-PYK2 level observed in
BMSCs of CKOCol3.6 mice (Fig. 7F,G). This suggested that the lack
of effect of FAK inhibition in osteoblasts on AKT andmTORC1 sig-
naling was likely due to the compensatory increase in PYK2 activ-
ity. Finally, we determined the effect of FAK kinase inhibition at
different differentiation stages on BMSC mineralization by von
Kossa staining (Fig. S13A). Our data showed that early FAK kinase
inhibition starting from day 1 or day 3 led to significantly
decreased mineralized nodule numbers; however, FAK kinase
inhibition starting from day 7 did not decrease BMSCmineraliza-
tion. Interestingly, the transient FAK kinase inhibition from day
1 to day 7 was sufficient to compromise the later mineralization
(Fig. S13B,C). Taken together, our data indicated that FAK kinase
activity has an important role in early osteoblast lineage cells but
not in late osteoblasts.
Fig. 5. FAK deficiency in osteoprogenitor cells leads to decreased mTORC1 signaling. (A,B) BMSCs isolated from CHet and CKODermo1 mice were analyzed
by western blot: (A) representative western blot images using indicated antibodies; (B) quantification of the relative level of signalingmolecules illustrated
in A (n = 5). FAK and β-catenin were normalized to Vinculin and phospho-proteins were normalized to the respective total proteins. (C,D) BMSCs isolated
from CHet-RFP and CKODermo1-RFP mice were analyzed by immunofluorescence using anti-p-S6 antibody: (C) Representative fluorescent image in day
7 culture. Yellow arrows indicate the RFP+p-S6+DAPI+cells; red arrows indicate the RFP+p-S6−DAPI+cells; green arrows indicate the p-S6−Ki67+DAPI+cells.
Scale bar = 100 μm. (D) Quantification of percentage of the p-S6 and RFP double positive cells illustrated in C (n = 3). Values are presented as median and
interquartile range.
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Dual inhibition of FAK kinase and PYK2 kinase decreases
mTORC1 signaling and compromises osteogenic
differentiation of BMSCs at later differentiation stage
To test the hypothesis that PYK2 compensates for the loss of FAK
at later differentiation stage of BMSCs, we determined the effect
of dual inhibition of FAK kinase and PYK2 kinase on mTORC1 sig-
naling by using FAK/PYK2 dual inhibitor PF-562,271(32) at a later
differentiation stage of BMSCs. First, our data showed that 1μM
FAK/PYK2 dual inhibitor effectively inhibited the levels of both
phospho-FAKTyr397 and phospho-PYK2Tyr402 (Fig. 9A–C) in wild-
type BMSCs. Next, the addition of FAK/PYK2 dual inhibitor start-
ing from day 7 BMSC culture significantly decreased themTORC1
signaling and the level of phospho-AKT in wild-type BMSCs
(Fig. 9D–F). Finally, our data showed that FAK/PYK2 dual inhibitor
treatment starting from day 7 culture inhibited osteogenic differ-
entiation and mineralization (Fig. S14). This inhibitory effect was
absent in FAK inhibitor treatment (Fig. S13, D7–D21 group),
Fig. 6. Fak deletion in osteoblasts does not affect bone development. (A) FAK and phospho-PYK2 (p-PYK2) protein levels were analyzed bywestern blot in
cortical bone isolated from femur and tibia of 1-month-old Fakflox/flox (Control) and Fakflox/flox;Col3.6-Cre (CKOCol3.6) male mice. (B) Representative image of
7-week-old control and CKOCol3.6 mice. (C) Body weight of male control and CKOCol3.6 mice at indicated ages (n = 16, 26, 22, 17, 10, and 6, in 1 week,
2 weeks, 3 weeks, 4 weeks, 7 weeks, and 6 months groups, respectively, for control mice; and n = 22, 34, 23, 17, 9, and 8, in 1 week, 2 weeks, 3 weeks,
4 weeks, 7 weeks, and 6 months groups, respectively, for CKOCol3.6 mice). (D) Body length of 7-week-oldmale control and CKOCol3.6 mice (n= 14 for control
mice, n = 10 for CKOCol3.6 mice). (E–L) μCT analysis of femoral trabecular and cortical bone in 2-month-old (2M) and 6-month-old (6M)malemice: (E) BV/TV,
(F) Tb.N, (G) Tb.Th, (H) Tb.Sp, (I) Ct.Th, (J) Ct.Ar, (K) Ec.Pm, (L) Ps.Pm (n = 15 and 5, in 2M and 6M groups, respectively, for control mice, n = 16 and 8, in 2M and
6M groups, respectively, for CKOCol3.6 mice). Values are presented as median and interquartile range. BV/TV = bone volume fraction; Ct.Ar = cortical bone
area; Ct.Th = average cortical thickness; Ec.Pm = endocortical perimeter; Ps.Pm = periosteal perimeter; Tb.N = trabecular number; Tb.Sp = trabecular spac-
ing; Tb.Th = trabecular thickness.
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highlighting the significant difference between these two
inhibitors.
To further determine the potential compensatory role of PYK2
when FAK is absent at later differentiation stage of BMSCs, we
used the BMSCs isolated from CKOCol3.6 mice because our data
showed that PYK2 activity was increased and there was no
change in the proliferation and differentiation in CKOCol3.6
BMSCs compared to controls (Fig. 7). As expected, the addition
of FAK/PYK2 dual inhibitor starting from day 7 significantly
decreased the phospho-PYK2 level in CKOCol3.6 BMSCs
(Fig. S15B). Importantly, dual inhibitor treatment decreased the
mTORC1 signaling and the level of phospho-AKT in CKOCol3.6
Fig. 7. Fak deletion in osteoblasts does not affect proliferation andmTORC1 activity. (A) Representative fluorescent images of Ki67 (green) and DAPI (blue)
staining in Fakflox/flox (Control) and Fakflox/flox;Col3.6-Cre (CKOCol3.6) BMSCs after 3 and 7 days of culture. Red arrowheads point to the Ki67+DAPI+cells. Scale
bar = 20 μm. (B) Quantification of the percentage of Ki67-positive BMSCs described in A (n = 3). (C) Quantification of BMSC cell number in the same culture
as A (n = 3). (D) ALP staining was performed after 7 days osteogenic culture of control and CKOCol3.6 BMSCs. Image was the representative of six indepen-
dent experiments. (E) AR staining was performed after 21 days osteogenic culture of control and CKOCol3.6 BMSCs. Image is representative of six indepen-
dent experiments. (F,G) Western blot was performed on lysates of BMSCs isolated from Fakflox/flox (Control) and Fakflox/flox;Col3.6-Cre (CKOCol3.6) mice: (F)
representative western blot image using indicated antibodies in day 0 (first day after plating) and day 7 cultures; (G) quantification of the relative protein
levels as illustrated in E. FAK and β-catenin were normalized to Vinculin and phospho-proteins were normalized to the respective total proteins (n = 4).
Values are presented as median and interquartile range. ALP = alkaline phosphatase; AR = Alizarin red.
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BMSCs (Fig. S15C,D). Last, although CKOCol3.6 BMSCs had compa-
rable osteogenic differentiation and mineralization potential
compared to control (Fig. S16A,B), FAK/PYK2 dual inhibitor treat-
ment starting from day 7 culture inhibited osteogenic differenti-
ation and mineralization in CKOCol3.6 BMSCs (Fig. S16C–G).
Altogether, our data showed that FAK regulates Wnt/β-
catenin signaling and mTORC1 signaling of osteoblast lineage
cells in a differentiation stage–dependent manner. FAK kinase
inhibition in early osteoprogenitor cells compromised mTORC1
signaling but its inhibition in osteoblasts did not compromise
mTORC1 signaling or in vitro mineralization because of the com-
pensation by upregulated active PYK2.
Discussion
We previously showed that Fak deletion by Osterix-Cre leads to
enhanced bone marrow adipogenesis in association with a sig-
nificant decrease in β-catenin level.(10) In this study we showed
that Fak deletion by Dermo1-Cre or Col3.6-Cre did not increase
bone marrow adipogenesis nor decreased β-catenin level, indi-
cating the regulation of β-catenin level by FAK is cell differentia-
tion stage–dependent. To support this notion, our data showed a
significant decrease in β-catenin level when FAK kinase activity
was inhibited by FAK-specific kinase inhibitor in BMSCs around
the start of Osterix expression but the earlier or later inhibition
of FAK kinase activity did not affect β-catenin level. Moreover,
an early transient FAK kinase inhibition surprisingly increased
β-catenin level, suggesting the complex regulatory mechanism
on β-catenin level by FAK. Our previous report also showed that
although Fak deletion in Osterix-expressing cells significantly
decreases the β-catenin level in BMSCs, it does not decrease
the β-catenin level in more mature calvarial osteoblasts.(10) The
underlying mechanism for the differential effects of FAK inhibi-
tion at different differentiation stages on β-catenin level remains
to be determined.
Through both genetic and pharmacological approaches, we
identified a novel regulatory function of FAK on mTORC1 signal-
ing in early osteoprogenitor cells. Our data also showed that FAK
positively regulated the phospho-AKT level in these cells. The
Fig. 8. FAK kinase inhibition decreases mTORC1 signaling of BMSCs in a cell differentiation stage-dependent manner. (A) Representative images of ALP
staining at indicated days of culture (n = 3). (B) Cartoon showing the experimental design of FAK inhibitor PF-573,228 treatment used in C and D. Dashed
red line represents no treatment, dashed black line represents vehicle treatment, and solid black line represents 1μM FAK inhibitor PF-573,228 treatment
at indicated culture time in different groups. There were two cohorts of culture: 7 days culture and 11 days culture. In cohort I, D1–D7means FAK inhibitor
was added from day 1 to day 7; D1–D3means FAK inhibitor was added from day 1 to day 3; D3–D7means FAK inhibitor was added from day 3 to day 7. In
cohort II, D7–D11 means FAK inhibitor was added from day 7 to day 11. (C) At the end of culture in each cohort, BMSCs were analyzed with indicated
antibodies. (D) Quantification of the relative level of the signaling molecules illustrated in cohort I (n = 3). (E) Quantification of the relative level of the sig-
naling molecules illustrated in cohort II (n = 3). Phospho-proteins were normalized to the respective total proteins and β-catenin was normalized to Vin-
culin. Values are presented as median and interquartile range. ALP = alkaline phosphatase.
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serine/threonine protein kinase AKT is a downstream effector of
PI3K. Because FAK positively regulates the PI3K/AKT pathway,(33)
and Fak overexpression can promote proliferation partly
through the PI3K/AKT pathway,(34) the proliferation defect in
FAK-deficient early osteoprogenitor cells is likely contributed
by the decrease in AKT signaling. Furthermore, AKT can promote
mTORC1 activity by inactivating tuberin,(35,36) and AKT deficiency
impairs cell proliferation in an mTORC1-dependent manner.(37)
Our data showed a concomitant decrease in both AKT and
mTORC1 signaling in FAK-deficient cells. Thus, the proliferation
defect in the mutant cells is potentially mediated through the
AKT/mTORC1 axis. AKT can phosphorylate mTOR at Thr2446
and Ser2448;(13) our data showed that FAK inhibition decreased
Ser2448 phosphorylation of mTOR, further supporting the
notion that FAK may regulate mTORC1 through AKT pathway.
It is generally believed that AKT-mediated mTORC1 regulation
applies to both S6K1 and 4EBP1 pathways because both S6K1
phosphorylation and 4EBP1 phosphorylation are significantly
decreased in the cells lacking AKT1 and AKT2.(38) However, it
has also been reported that knockdown of Akt1, Akt2, and Akt3
in bladder cancer cell lines specifically decreases S6K1 phosphor-
ylation but not 4EBP1 phosphorylation level.(39) In addition,
silencing or pharmacological inhibition of mTOR suppresses
S6K1 but not 4EBP1 phosphorylation in the same cancer cell
lines.(39) Thus, it was proposed that 4EBP1 phosphorylation is
regulated independent of the AKT/mTORC1 axis. In our study,
FAK-deficient early osteoprogenitor cells had decreased phos-
phorylation of AKT and mTOR, and mTORC1 signaling was only
defective in the S6K1 branch, but not the 4EBP1 branch. This sug-
gests that similar regulatory mechanisms exist in early
Fig. 9. Dual inhibition of FAK kinase and PYK2 kinase decreases mTORC1 signaling of BMSCs at later differentiation stage. (A) Representative western blot
image showing that p-FAK and p-PYK2 levels in BMSCs were dose-dependently suppressed by FAK/PYK2 dual inhibitor PF-562,271. (B,C) Quantification of
the relative p-FAK level (B) and p-PYK2 level (C) illustrated in A (n = 4). p-FAK and p-PYK2 levels were normalized by their respective total protein levels. (D)
Cartoon showing the experimental design of FAK/PYK2 dual inhibitor PF-562,271 treatment used in E and F. Dashed red line indicates no treatment,
dashed black line indicates vehicle treatment, and solid black line indicates 1μMPF-562,271 treatment. D7–D11means FAK/PYK2 dual inhibitor was added
from day 7 to day 11. (E) BMSCs were collected at day 11 and extracted proteins were analyzed by western blot using indicated antibodies. (F) Quantifi-
cation of the relative protein level illustrated in E. Phospho-proteins were normalized to the respective total proteins and β-catenin was normalized to
Vinculin (n = 3). Values are presented as median and interquartile range. p-FAK = phospho-FAK; p-PYK2 = phospho-PYK2.
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osteoprogenitor cells compared to the reported bladder cancer
cell lines. However, the mechanism of FAK’s selective regulation
on S6K1 pathway in early osteoprogenitor cells remains to be
determined.
In this study, we used Col3.6-Cre transgenic mice to target
osteoblasts. We previously characterized its expression and
activity.(20) A recent study by Rajshankar and colleagues(11) used
this same transgenic mouse to delete Fak in osteoblasts and
showed a very different phenotype from ours. In that study, it
was shown that the Fak conditional knockout mice are much
shorter, have severely crooked and much shorter tails, and have
a significant decrease in bone mass. None of these phenotypes
was observed in our Fak conditional knockout mice using the
same Col3.6-Cre. There are two potential explanations for these
discrepancies. First is the difference in genetic background. The
mice used in Rajshankar and colleagues(11) were B6/CD-1 mixed
background and ours had been backcrossed for at least eight
generations onto a C57BL/6 background. Second is the differ-
ence in the Fak floxed mouse line. Rajshankar and colleagues(11)
used the Fak floxed mice generated by Drs. Beggs and
Reichardt’s group in which LoxP sites flank the second kinase
domain exon.(40) In this study, we used the Fak floxed mice that
we previously generated by flanking the third coding exon,
which is located at its FERM domain.(5) Cre-mediated deletion
of exon 3 leads to a frameshift mutation and produces a small
truncated and nonfunctional peptide.
In this report, we showed that Fak deletion in Dermo1-
expressing early osteoprogenitor cells had defective prolifera-
tion due to a decrease in mTORC1 activity. In contrast, Fak
deletion in osteoblasts had no significant effect on proliferation
and differentiation as well as mTORC1 activity. Our data sug-
gested that FAK is dispensable in mature osteoblasts and this is
likely due to the compensatory role of PYK2, which belongs to
the same non–receptor tyrosine kinase family as FAK.(41) We
draw this conclusion because: (i) our data and another study(9)
showed an upregulation of PYK2 activity in FAK-deficient osteo-
blasts; (ii) our data showed that FAK/PYK2 dual inhibitor but not
FAK inhibitor decreased mTORC1 signaling and inhibited the
osteogenic differentiation of BSMCs if added at a later differenti-
ation stage (after the expression of Osterix); and (iii) our data
showed that Fak deletion in osteoblasts using Col3.6-Cre did
not affect the mTORC1 signaling and differentiation of BMSCs,
but the additional inhibition of PYK2 kinase decreased mTORC1
signaling and compromised BMSC differentiation. In addition, a
previous study showed that PYK2 knockdown reduces S6K1
expression and phosphorylation in prostate cancer cells.(42)
In summary, our study identified a novel FAK-mTORC1 signal-
ing axis mediated by the kinase-dependent function of FAK in
regulating cell proliferation, and this signaling cascade specifi-
cally operates in the early osteoprogenitor cells but not in osteo-
blasts. As a result, Fak deletion in early osteoprogenitor cells led
to osteopenia in mice but its deletion in osteoblasts did not
affect bone development. Altogether, our studies suggested that
FAK plays differential roles at different differentiation stages of
osteoblast lineage cells: in early osteoprogenitor cells, it pro-
motes the proliferation via positively regulating mTORC1 signal-
ing; in committed osteoblast precursors, it promotes osteoblast
proliferation and differentiation via positively regulating both
mTORC1 and Wnt/β-catenin signaling; and in osteoblasts, the
loss of FAK can be compensated by upregulated active PYK2
(Fig. 10).
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